NCT00898911已完成不适用
Prediction of Overall Survival Using Mass Spectrometry Profiling in Head and Neck Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitors
ECOG-ACRIN Cancer Research Group0 个研究点目标入组 30 人开始时间: 2008年7月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 主要终点
- Overall survival measured in weeks
研究概览
简要总结
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at blood sample analysis in predicting overall survival in patients with recurrent or metastatic head and neck cancer.
详细描述
OBJECTIVES:
- To validate the mass spectrometry profile that is predictive of survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with EGFR inhibitors.
OUTLINE: Plasma and serum samples are analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and classified according to prognosis ("good" vs "poor") using a previously developed predictive algorithm.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Overall survival measured in weeks
时间窗: 1 month
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
DNA Variations in the Gene in Young Patients With Wilms' TumorKidney CancerNCT00088803Children's Oncology Group471
已完成
不适用
Studying Biomarkers in Samples From Patients With RhabdomyosarcomaSarcomaNCT01433237Children's Oncology Group40
已完成
不适用
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic MelanomaKidney CancerMelanoma (Skin)NCT00617799University of Nebraska15
已完成
不适用
Trastuzumab in Treating Women With Metastatic Breast CancerBreast CancerNCT00896376Centre Antoine Lacassagne49
已完成
不适用
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon TherapyMelanoma (Skin)NCT00897520ECOG-ACRIN Cancer Research Group40